The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors: Implications for Once-Daily Dosing
暂无分享,去创建一个
C. Flexner | D. Back | J. Gerber | D. Burger
[1] W. Dolmans,et al. Nevirapine Plasma Concentrations are Still Detectable After More Than 2 Weeks in the Majority of Women Receiving Single-Dose Nevirapine: Implications for Intervention Studies , 2005, Journal of acquired immune deficiency syndromes.
[2] D. Podzamczer,et al. Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz , 2005, Antiviral therapy.
[3] V. Soriano,et al. Combinations of nucleoside/nucleotide analogues for HIV therapy. , 2004, AIDS reviews.
[4] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[5] M. Saag,et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. , 2004, JAMA.
[6] P. Musoke,et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. , 2004, AIDS research and human retroviruses.
[7] Christopher D Pilcher,et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.
[8] F. Gutiérrez,et al. Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine? , 2004, Journal of acquired immune deficiency syndromes.
[9] A. Ray,et al. Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir , 2004, Antimicrobial Agents and Chemotherapy.
[10] I. James,et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] K. Lichtenstein,et al. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] Edwin DeJesus,et al. Pharmacodynamic Effects of Zidovudine 600 mg Once/Day versus 300 mg Twice/Day in Therapy‐Naïve Patients Infected with Human Immunodeficiency Virus , 2004, Pharmacotherapy.
[13] M. Juan,et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load , 2004, AIDS.
[14] D. Hoelscher,et al. Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily , 2004, Antimicrobial Agents and Chemotherapy.
[15] A. Muriel,et al. High Rate of Didanosine-Related Mitochondrial Toxicity in HIV/HCV-Coinfected Patients Receiving Ribavirin , 2004, Antiviral therapy.
[16] C. Fletcher,et al. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals , 2003, AIDS.
[17] G. Moyle. The Assessing Patients’ Preferred Treatments (APPT-1) study , 2003, International journal of STD & AIDS.
[18] J. Rodman,et al. Metabolism of Tenofovir and Didanosine in Quiescent or Stimulated Human Peripheral Blood Mononuclear Cells , 2003, Pharmacotherapy.
[19] S. Chou,et al. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] S. Khoo,et al. Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea , 2002, AIDS.
[21] E. Dejesus,et al. Lamivudine 300 mg QD Versus Continued Lamivudine 150 mg BID with Stavudine and a Protease Inhibitor in Suppressed Patients , 2002, HIV clinical trials.
[22] Richard D Moore,et al. Hepatitis C and progression of HIV disease. , 2002, JAMA.
[23] R. Schooley,et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF , 2002, AIDS.
[24] J. Montaner,et al. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. , 2002, AIDS.
[25] Z. Hong,et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection , 2002, Hepatology.
[26] K. Tashima,et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] J. Cramer,et al. A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.
[28] Joseph Quinn,et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.
[29] Alex J White,et al. Mitochondrial toxicity and HIV therapy , 2001, Sexually transmitted infections.
[30] S. Piscitelli,et al. Interactions among drugs for HIV and opportunistic infections. , 2001, The New England journal of medicine.
[31] A. Lafeuillade,et al. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection , 2001, The Lancet.
[32] D. Back,et al. Correlation between Intracellular Pharmacological Activation of Nucleoside Analogues and HIV Suppression in Vitro , 2000, Antiviral chemistry & chemotherapy.
[33] C. Perry,et al. Abacavir , 2000, Drugs.
[34] S. Weller,et al. Population Pharmacokinetics and Pharmacodynamic Modeling of Abacavir (1592U89) from a Dose-Ranging, Double-Blind, Randomized Monotherapy Trial with Human Immunodeficiency Virus-Infected Subjects , 2000, Antimicrobial Agents and Chemotherapy.
[35] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[36] P. Jatlow,et al. Interaction of methadone with didanosine and stavudine. , 2000, Journal of acquired immune deficiency syndromes.
[37] D. Richman,et al. In vivo antagonism with zidovudine plus stavudine combination therapy. , 2000, The Journal of infectious diseases.
[38] J. Lisziewicz,et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] D. Stein,et al. Pharmacokinetic Interaction of Abacavir (1592U89) and Ethanol in Human Immunodeficiency Virus-Infected Adults , 2000, Antimicrobial Agents and Chemotherapy.
[40] D. Back,et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. , 1999, AIDS.
[41] A. Heredia,et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. , 1999, Journal of acquired immune deficiency syndromes.
[42] C. Hart,et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. , 1998, AIDS research and human retroviruses.
[43] D. Jung,et al. Effect of High‐Dose Oral Ganciclovir on Didanosine Disposition in Human Immunodeficiency Virus (HIV)‐Positive Patients , 1998, Journal of clinical pharmacology.
[44] D. Back,et al. Lamivudine (3TC) phosphorylation and drug interactions in vitro. , 1997, Biochemical pharmacology.
[45] J. Eron,et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim‐sulfamethoxazole , 1996, Clinical pharmacology and therapeutics.
[46] B. Sadler,et al. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine , 1996, Clinical pharmacology and therapeutics.
[47] N. Hyslop,et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus , 1994, Clinical pharmacology and therapeutics.
[48] A. Pesce,et al. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus , 1994, Antimicrobial Agents and Chemotherapy.
[49] H. Mitsuya,et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. , 1994, The Journal of biological chemistry.
[50] J. Beijnen,et al. Pharmacokinetic interaction between rifampin and zidovudine , 1993, Antimicrobial Agents and Chemotherapy.
[51] S. Broder,et al. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. , 1991, Molecular pharmacology.
[52] W. Elmquist,et al. Probenecid Inhibits the Metabolic and Renal Clearances of Zidovudine (AZT) in Human Volunteers , 1990, Pharmaceutical Research.
[53] C. Hendrix,et al. PROBENECID AND ZIDOVUDINE METABOLISM , 1989, The Lancet.
[54] E. De Clercq,et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro , 1987, Antimicrobial Agents and Chemotherapy.
[55] R. Deitch. The losing battle against drug addiction. , 1984, Lancet.
[56] B. Kearney,et al. Tenofovir Disoproxil Fumarate , 2004, Clinical pharmacokinetics.
[57] L. Scott,et al. Emtricitabine , 2012, Drugs.
[58] R. Bruno,et al. Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice and Once Daily Administration in Patients with HIV , 2001, Clinical pharmacokinetics.
[59] J. Bartlett,et al. Product information , 2001, Transplantation.